OS Therapies (NYSEAMERICAN:OSTX) Releases Earnings Results

OS Therapies (NYSEAMERICAN:OSTX) announced its quarterly earnings data on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, FiscalAI reports.

OS Therapies Stock Performance

Shares of NYSEAMERICAN:OSTX opened at $1.88 on Monday. The company has a market capitalization of $74.32 million, a PE ratio of -1.90 and a beta of -1.34. OS Therapies has a twelve month low of $1.15 and a twelve month high of $2.57. The firm has a 50 day simple moving average of $1.52 and a 200-day simple moving average of $1.55.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. D. Boral Capital reissued a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a report on Thursday, April 30th. Zacks Research lowered shares of OS Therapies from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $18.50.

Hedge Funds Weigh In On OS Therapies

Institutional investors have recently modified their holdings of the business. Susquehanna International Group LLP acquired a new position in shares of OS Therapies in the 3rd quarter valued at $29,000. Jane Street Group LLC acquired a new position in OS Therapies in the 4th quarter valued at $39,000. Ground Swell Capital LLC purchased a new stake in shares of OS Therapies during the 3rd quarter worth $40,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of OS Therapies during the 3rd quarter worth $40,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of OS Therapies during the 2nd quarter worth $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.